Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
MGI Pharma
September 24, 2013
EP Vantage interview – Tesaro team limbers up for the second time
April 07, 2011
SuperGen and Astex striving to reach the next level
April 07, 2011
SuperGen and Astex striving to reach the next level
August 25, 2010
Therapeutic focus - Will hopes evaporate as gene therapy pipeline flows?
May 17, 2010
OSI deal sees Astellas finally join its peers with a major overseas acquisition
April 16, 2010
Abraxis potential sale could hinge on valuation
July 06, 2009
EP Vantage Interview - Eisai expects results from accountable research units
May 18, 2009
IDM and Victory snapped up as Japanese appetite for overseas deals continues
February 26, 2009
Event - Glaxo's new anti-emetic pill nearing FDA decision
September 01, 2008
Shionogi joins move westward with Sciele buy
August 08, 2008
EU companies making US M&A hay while euro shines
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
April 22, 2021
Evaluate Vantage Report: US Approvals Under the Spotlight
Editor's Picks
June 07, 2021
Biogen makes history with Alzheimer’s approval
June 08, 2021
Biogen and the social contract
June 09, 2021
Asco 2021 story roundup
June 03, 2021
Asco 2021 justifies Novartis’s radioligand Vision
May 26, 2021
Roche remains big pharma’s biggest R&D spender
